New study tests personalised care to combat brain fog in Graves' disease
NCT ID NCT06309316
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a person-centred care (PCC) programme, delivered by phone and online, can help people with Graves' disease feel better mentally and return to work. 220 adults with first-time Graves' disease will be randomly assigned to receive either usual care or usual care plus PCC for 12-18 months. The main goal is to see if PCC improves self-efficacy and reduces sick leave after 3 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- person-centred care (PCC) via phone and web platform
- What this could lead to
- If it works, this could offer a practical, non-drug way to reduce mental fatigue and sick leave for people with Graves' disease, and may be applied to other conditions.
- What could go wrong
- This is a relatively small, early-stage trial testing a behavioural intervention, not a drug. The effect may be modest, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 220 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2024
- Expected to finish
-
Jan 2030
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18-65 years * First time Graves' diseases with elevated FT4 and/or FT3 and positive TSH receptor antibody (TRAb) Exclusion Criteria: * Patients that cannot attend to the protocol * Patients with moderate-severe/ severe Graves' eye disease
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Graves disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Agneta Lindo
RECRUITINGGothenburg, 413 45, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two autoimmune conditions, one child: study probes hidden thyroid trouble
- Eye damage in Graves' disease: can early clues predict who is at risk?
- Why does Graves' disease leave some brains exhausted? scientists hunt for clues in blood and spinal fluid
- Hidden thyroid cancers may be more common in Graves' disease than thought
- Can a steroid shot make thyroid surgery safer?
- Targeting the immune system: a new antibody may free Graves' patients from daily drugs